260660 — Korea Arlico Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapNeutral

Annual income statement for Korea Arlico Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	—	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	124,809	140,157	167,737	187,155	190,436
Cost of Revenue
Gross Profit	79,808	87,529	106,924	110,179	99,796
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	114,210	135,363	157,873	184,082	195,522
Operating Profit	10,599	4,794	9,864	3,073	-5,086
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9,728	5,605	8,391	3,476	-6,174
Provision for Income Taxes
Net Income After Taxes	8,372	4,930	8,034	3,061	-5,358
Net Income Before Extraordinary Items
Net Income	8,372	4,930	8,034	3,061	-5,358
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	8,372	4,930	8,720	1,755	-5,358
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	566	271	550	104	-377
Dividends per Share